Drug Detail

Information about Gleevec + Genasense

Generic Name
Imatinib + Oblimersen
STI-571 + G3139
Brand Name (US)
Gleevec + Genasense
Novartis + Genta
Drug Type
Tyrosine Kinase Inhibitor + Antisense
Oral + Intravenous
Approval Status
Gleevec is approved for GIST. This combination was evaluated in a phase 2 trial for GIST.
Overall Strategy
GIST cell based
Block KIT + Unblock cell death genes
Drug Category
KIT/PDGFRA inhibitor + Bcl-2 inhibitor

Genasense is an drug that reduces the expression of the Bcl-2 protein using a technology known as Antisense. Bcl-2 is an "anti-apoptosis" protein; it prevents cells from dying. By blocking bcl-2, cancer therapies might kill more tumor cells.
Genasense is not an approved drug. In trials, it is typically combined with some other type of cancer therapy in an attempt to make the therapy more effective.
Gleevec is the approved first-line therapy for GIST.